Simulations Plus

“For Biotech companies, finding strategic partnerships is a necessity in streamlining our development programs to save time and money. Simulations Plus nimbly partnered on a program to not only develop a PBPK model, but to also develop a DDI regulatory roadmap that informed our regulatory approach towards NDA filing and helped to design the next steps of our program. Their knowledge of the area and ease of partnering exceeded my expectations.”

Sr. Vice President, Pharmaceutical Sciences
“I’d like to give some feedback regarding the excellent prediction work that you performed previously. We have received the results from the clinical phase 1b cohort now and have been able to compare the test item concentrations to those predicted in the model that you created. The predictions are really amazingly accurate!”
Head of Nonclinical Development
“Just wanted to drop a quick note and take the opportunity to highlight the excellent software application support the team has provided for GastroPlus. I really don’t think I would have got to where we have on my own but feel much better positioned now to use some of these additional features in the software. The team has excellent customer focus, and I really like the style and manner in which you interact with the user.”
Lead Specialist
“Often clients are fast and furious to send complaint notes to the CRO, but silent when things are going well. Good work equally needs appreciation & recognition. I am pleased to tell you that I am very happy with the progress of our project at Simulations Plus.”
Sr. Director, Translational Drug Development
January 3, 2024
Welcome to Simulations Plus, Daniel Szot, Chief Rev. Officer

2024 Employee Highlights

November 8, 2023
VP of Pharmacometrics Amparo de la Peña, a leader in pharmacometric solutions at Simulations Plus, joins ISoP Board.

2023 Employee Highlights

February 15, 2023
A dynamic graphic highlights "Simulations Plus" with MIDD+ 2023, bursting on a dark backdrop.

MIDD+ 2023 Online Conference

Third annual conference on model-informed drug development strategies from discovery through post-approval phases. Watch Session Replays

November 3, 2022
Welcome to the 2022 team announcement for Gustavo Mendes Lima Santos, our featured Regulatory Affairs Fellow at Simulations Plus, showcased in Employee Highlights.

2022 Employee Highlights

  • Gustavo Mendez Lima Santos Joins Simulations Plus (Formerly Anvisa, Brazil) (11/3/22)
  • Renée Bouché celebrates 21 years at Simulations Plus (10/29/22)
  • Frederico Martins Joins Simulations Plus (Formerly esqLABS, Galapagos Pharmaceuticals, Certara) (10/24/22)
  • Xavier Pepin Joins Simulations Plus (Formerly AstraZeneca & Sanofi) (5/2/22)
  • Anant Ketkar Joins Simulations Plus (Formerly IQGEN-X Pharma, India) (4/11/22)
July 14, 2022
A gloved hand holds a pipette over a tray in a lab, showcasing Simulations Plus modeling tools.

Concierge Program Launched

Providing one-on-one support for our clients and partners as they navigate the long and winding road of model-informed drug discovery. Learn More

February 16, 2022
The banner highlights "Simulations Plus MIDD+," celebrating 25 years, with a sign-up for experts.

2nd Annual MIDD+ 2022 Virtual Conference

Improving Health Through Innovative Solutions in Model-Based Drug Discovery. Watch Session Replays

November 30, 2021
Simulations Plus marks 25 years with a $25K gift to Dispensary of Hope, featured with logo.

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

Expanding access to high-quality medication for people in need Read More

November 18, 2021
NAFLDsym depicts highlighted lungs and liver in a transparent torso, set against blue hues.

Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference

Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials. Read More

October 21, 2021
A hexagonal graphic with a "U+" icon and images of diverse professionals on a blue-gray backdrop.

Simulations Plus Announces the University+ Program

Free access to Simulations Plus software for accredited universities will accelerate learning and educational pursuits. Learn More

July 8, 2021
Celebrating 25 years, festive graphics with colorful confetti meet precise simulation modeling.

Simulations Plus Celebrates 25 Years in Business

“We are very proud and humbled by our achievements at SLP over these past 25 years and look forward to celebrating this milestone over the next year with our clients, employees, and collaborators,” said Shawn O’Connor, CEO. Learn More

May 12, 2021
A digital backdrop with vertical blue lines and numbers evokes DILIsym's tech-inspired effects.

Simulations Plus Uplisted to The Nasdaq Global Select Market®

Strong growth, innovation, and global reach drive the company’s progress. Read More

March 3, 2021
Simulations Plus MIDD Conference 2021 featured virtual booths with premier modeling software.

Hosts The Inaugural 2021 MIDD+ Scientific Conference

Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More

September 15, 2020
ADMET Predictor 10.0 with AI-Driven Drug Design by Simulations Plus revolutionizes drug prediction.

Releases ADMET Predictor® Version 10.0 (APX™)

Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More

August 10, 2020
Simulations Plus stock data is prominently displayed on NASDAQ's dynamic market simulation.

Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock

Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More

April 1, 2020
Simulations Plus (@SimulationsPlus) and Lixoft logos with S+ design & icons on a molecular backdrop.

Lixoft becomes a subsidiary of Simulations Plus

Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More

January 6, 2020
Images highlight Grace Fraczkiewicz with ADMET Predictor, DILIsym, and consultation badges.

Grace Fraczkiewicz Celebrates 20 Years of Service

In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About Her Journey

August 6, 2018
Collage: Robert Fraczkiewicz with Simulations Plus poster, 20-year emblem & team celebration.

Robert Fraczkiewicz Celebrates 20 Years of Service

In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About His Journey

June 26, 2018
CEO Shawn O'Connor smiles beside Simulations Plus's future statement, featuring its logo.

Simulations Plus Names Shawn O’Connor as CEO

Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More

February 1, 2018
ADMET Predictor® excels in SAMPL6 pKa Challenge, 1st among empirical methods, Feb 2018.

S+pKa Model Wins SAMPL6 pKa Challenge

Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More

June 1, 2017
Stylized liver art promotes DILIsym® Services & Simulations Plus: Science + Software = Success.

DILIsym Services, Inc. Becomes a Subsidiary of Simulations Plus

DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More

October 10, 2016
Congrats ISoP Fellow Jill Fiedler-Kelly of Simulations Plus' Pharmacometrics Services!.

Jill Fiedler-Kelly Named Fellow of ISoP

Jill Fiedler-Kelly awarded with ISoP Fellowship for her professional excellence and superior impact in pharmacometrics, and for substantial volunteering work for ISoP on October, 2016. Learn More

August 25, 2016
PKPlus™ 1.0: Validation and value with advanced pharmacokinetics by Simulations Plus.

Simulations Plus Releases PKPlus™ Version 1.0

Simulations Plus released version 1.0 of PKPlus™, its next-generation software for analysis of preclinical and clinical trial data. Learn More

December 9, 2014
An orange background features a white "F" and curved arrow, embodying Simulations Plus innovation.

First Commercial Simulx Version

Lixoft released version 1.0 of Simulx, an easy, efficient and flexible application for clinical trail simulations, on December 2014. Learn More

October 21, 2014
MembranePlus™ is Simulations Plus’ in vitro permeability software featuring Version 1.0.

MembranePlus™ Version 1.0 Released

Simulations Plus announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus™ simulation software on October 2014. Learn More

September 2, 2014
Simulations Plus COGNIGEN: Modeling, PK/PD simulation, and Pharmacometrics—Science. Success.

Cognigen Corporation Becomes a Subsidiary of Simulations Plus

Cognigen became a wholly-owned subsidiary of Simulations Plus on September 2014. Learn More

July 7, 2014
The image features "Introduction to Pop PK/PD with NLME" by Simulations Plus, with two portraits.

Joel and Jill published “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models”

Joel S. Owen and Jill Fiedler-Kelly published a textbook on “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models” on July 2014. Read More

March 4, 2013
A man in black with ASCPT logo celebrates Ted Grasela's Simulations Plus milestone.

Ted Grasela Awarded With The Gary Neil Prize from ASCPT

Dr. Grasela was awarded the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics(ASCPT). Learn More

January 9, 2012
The image features the DILIsym logo and a Venn diagram with "DILI Mechanisms," highlighting Version 1A.

DILIsym® Version 1A Released

DILIsym® Version 1A was released on January 2012. Learn More

October 3, 2011
The blue arrow curving around a circle on blue embodies MonolixSim Innovation & Computational Power.

First commercial Monolix® Version 1.0

Monolix® Version 1.0 was released on October 2011. Learn More

July 7, 2009
Simulations Plus on FSB 100 List: PBPK modeling & AI-driven drug discovery breakthrough.

Simulations Plus Named to Fortune Small Business FSB 100 List

Simulations Plus has been named to the ninth annual Fortune Small Business FSB 100 list of the fastest-growing small public companies in America. Learn More

February 9, 2005
DDDPlus™: Advanced dissolution simulation by Simulations Plus, with 3D mortar graphic.

DDDPlus™ 1.0 Released

Simulations Plus released version 1.0 of DDDPlus™, a simulation of in vitro dissolution experiments for formulation scientists in the pharmaceutical industry on February 2005. Learn More

January 4, 2005
Promotional image for ADMET Predictor, the leading Simulations Plus software for fast ADMET analysis.

ADMET Predictor™ 1.0 Released

Simulations Plus released version 1.0 of ADMET Predictor™, formerly known as QMPRPlus™ on January 2005. Learn More

July 1, 1999
The Simulations Plus NASDAQ-listed logo stands out on a stock board with market data streaming.

Simulations Plus Listed on The NASDAQ

In 1999, Simulations Plus listed on the NASDAQ (American Stock Exchange) under the symbol SLP.

July 1, 1998
GastroPlus Version 1.0 logo with human intestines, “©1998 Simulations Plus, Inc.” displayed.

GastroPlus® Version 1.0 Released

Simulations Plus releases its flagship PBPK modeling and simulation, GastroPlus®, in July 1998. Learn More

July 1, 1996
Seven colleagues pose by the "Simulations Plus: Science and Software Integration" banner in CA.

Simulations Plus Incorporated in Lancaster, California

Simulations Plus incorporated in Lancaster, California in July 1996.